Qualigen Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Alpha Capital Anstalt has filed an Amendment No. 4 to Schedule 13G, reporting beneficial ownership of 0.51% of ALXCRYPTO HOLDINGS, INC. common stock.
Alpha Capital Anstalt has reported a 9.056% beneficial ownership stake in Qualigen Therapeutics, Inc., holding 153,545 shares of common stock.
Alpha Capital Anstalt has updated its beneficial ownership in Qualigen Therapeutics, Inc., reporting a 2.223% stake.